These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8501981)

  • 1. Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysis.
    Minderman H; Slocum HK; Malmberg M; Haanen C; Rustum YM
    Leukemia; 1993 Jun; 7(6):872-7. PubMed ID: 8501981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
    Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
    Kuffel MJ; Reid JM; Ames MM
    Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
    Bogush T; Robert J
    Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage.
    Woods KE; Ellis AL; Randolph JK; Gewirtz DA
    Cancer Res; 1989 Sep; 49(17):4846-51. PubMed ID: 2758416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells.
    Fukushima T; Ueda T; Uchida M; Nakamura T
    Int J Hematol; 1993 Apr; 57(2):121-30. PubMed ID: 8494991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
    Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
    Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H; Nguyen-Ba G; Lampidis TJ
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
    Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
    Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
    Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM
    Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin.
    Minderman H; Linssen P; Wessels J; Haanen C
    Anticancer Res; 1993; 13(4):1161-5. PubMed ID: 8352539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
    Curtis JE; Minden MD; Minkin S; McCulloch EA
    Leukemia; 1995 Mar; 9(3):396-404. PubMed ID: 7533865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin.
    Cairo MS; Toy C; Sender L; van de Ven C
    J Leukoc Biol; 1990 Mar; 47(3):224-33. PubMed ID: 2155275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox).
    Minderman H; Buscaglia MD; Rustum YM
    Leukemia; 1994 Aug; 8(8):1401-5. PubMed ID: 8057680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarubicin: an anthracycline antineoplastic agent.
    Cersosimo RJ
    Clin Pharm; 1992 Feb; 11(2):152-67. PubMed ID: 1551297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
    Zhong L; Shen H; Huang C; Jing H; Cao D
    Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S; Goto N; Nakamura T; Ueda T
    Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.